{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:43:43Z","timestamp":1792226623313,"version":"4.4.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The estimated prevalence of anti-HCV was 3.1% in Taiwan. Studies have shown iatrogenic behavior was the major transmission route. It is highest in specific populations including patients with end stage renal disease (ESRD), human immunodeficiency virus infection, who inject drug (PWID), and under opioid substitution treatment. Approximately 405,160 patients were seropositive for HCV RNA and in need of treatment.<\/jats:p>\n               <jats:p>Taiwan government claims to reach WHO\u2019s 2030 goal of HCV elimination by 2025 and works hard to resolve several barriers of HCV elimination including political commitment, sustainable financing, minimize reimbursement restrictions, instituted monitoring, and perform micro-elimination of specific populations. The last stage of HCV elimination is to accelerate the universal HCV screening program of populations aged 45-79 years and resolve the unawareness issue of HCV infection. Hopefully, we can achieve the targets of HCV elimination set by WHO and reach the goal earlier in 2025.<\/jats:p>","DOI":"10.1093\/infdis\/jiad016","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:00:18Z","timestamp":1694624418000},"page":"S180-S188","source":"Crossref","is-referenced-by-count":28,"title":["Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan"],"prefix":"10.1093","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-4695","authenticated-orcid":false,"given":"Rong-Nan","family":"Chien","sequence":"first","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"},{"name":"Liver Research Unit, Linkou Chang Gung Memorial Hospital and University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"},{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Hui-Min Wu","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"},{"name":"Department of Physical Therapy and Assistive Technology, National Yang Ming Chiao Tung University , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoh-Fang","family":"Pwu","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"},{"name":"School of Health Care Administration, Taipei Medical University , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Pen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chung","family":"Chen","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Jen","family":"Chen","sequence":"additional","affiliation":[{"name":"Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare , Taipei , Taiwan"},{"name":"Genomics Research Center, Academia Sinica , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"2023091316595833900_jiad016-B1","author":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan, ROC"},{"key":"2023091316595833900_jiad016-B2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"2023091316595833900_jiad016-B3","volume-title":"Global health sectors strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis","author":"World Health Organization (WHO)","year":"2016"},{"key":"2023091316595833900_jiad016-B4","volume-title":"Taiwan hepatitis C policy guidelines 2018\u20132025","year":"2019"},{"key":"2023091316595833900_jiad016-B5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1473-3099(19)30170-7","article-title":"Taiwan commits to eliminating hepatitis C in 2025","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023091316595833900_jiad016-B6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/liv.14412","article-title":"Taiwan is on track of accelerating hepatitis C elimination by 2025","volume":"40","author":"Wu","year":"2020","journal-title":"Liver Int"},{"key":"2023091316595833900_jiad016-B7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jfma.2018.10.021","article-title":"Achieving hepatitis C elimination in Taiwan-overcoming barriers by setting feasible strategies","volume":"117","author":"Wu","year":"2018","journal-title":"J Formos Med Assoc"},{"key":"2023091316595833900_jiad016-B8","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/ijc.22045","article-title":"Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan","volume":"119","author":"Lu","year":"2006","journal-title":"Int J Cancer"},{"key":"2023091316595833900_jiad016-B9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1440-1746.1997.tb00482.x","article-title":"Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan","volume":"12","author":"Lu","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"2023091316595833900_jiad016-B10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0035-9203(99)90012-3","article-title":"A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan","volume":"93","author":"Wang","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2023091316595833900_jiad016-B11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","article-title":"Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants","volume":"106","author":"Chen","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"2023091316595833900_jiad016-B12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1440-1746.2006.04489.x","article-title":"Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan","volume":"22","author":"Tsai","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"2023091316595833900_jiad016-B13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep4.1531","article-title":"Secular trends and geographic maps of hepatitis C virus infection among 4 million blood donors in Taiwan from 1999 to 2017","volume":"4","author":"Chen","year":"2020","journal-title":"Hepatol Commun"},{"key":"2023091316595833900_jiad016-B14","first-page":"605","article-title":"Incidence of hepatitis C infection in a hepatitis C endemic township in southern Taiwan","volume":"13","author":"Lu","year":"1997","journal-title":"Kaohsiung J Med Sci"},{"key":"2023091316595833900_jiad016-B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jmv.1097","article-title":"Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors","volume":"65","author":"Sun","year":"2001","journal-title":"J Med Virol"},{"key":"2023091316595833900_jiad016-B16","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jfma.2021.12.019","article-title":"Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: a nationwide survey in 2010\u20132018","volume":"121","author":"Lee","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"2023091316595833900_jiad016-B17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/infdis\/162.4.817","article-title":"Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"key":"2023091316595833900_jiad016-B18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","article-title":"Treatment of hepatitis C virus infection in patients with end-stage renal disease","volume":"26","author":"Liu","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"2023091316595833900_jiad016-B19","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1038\/s41598-021-87975-5","article-title":"Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan","volume":"11","author":"Lu","year":"2021","journal-title":"Sci Rep"},{"key":"2023091316595833900_jiad016-B20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094791","article-title":"Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection","volume":"9","author":"Hsieh","year":"2014","journal-title":"PLoS One"},{"key":"2023091316595833900_jiad016-B21","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/v14081637","article-title":"Collaborative referral model to achieve hepatitis C micro-elimination in methadone maintenance treatment patients during the COVID-19 pandemic","volume":"14","author":"Tai","year":"2022","journal-title":"Viruses"},{"key":"2023091316595833900_jiad016-B22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139687","article-title":"National trend and characteristics of acute hepatitis C among HIV infected individuals: a matched case-control study\u2014Taiwan, 2001\u20132014","volume":"10","author":"Lo","year":"2015","journal-title":"PLoS One"},{"key":"2023091316595833900_jiad016-B23","article-title":"Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"2023091316595833900_jiad016-B24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jfma.2011.06.022","article-title":"Seroprevalence of hepatitis virus infection in men who have sex with men aged 18\u201340 years in Taiwan","volume":"111","author":"Tseng","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"2023091316595833900_jiad016-B25","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/v13071316","article-title":"Hepatitis C virus subtypes novel 6g-related subtype and 6w could be indigenous in southern Taiwan with characteristic geographic distribution","volume":"13","author":"Tung","year":"2021","journal-title":"Viruses"},{"key":"2023091316595833900_jiad016-B26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","article-title":"Hepatitis C virus infection in Taiwan: past, present and future","volume":"115","author":"Kao","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"2023091316595833900_jiad016-B27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","article-title":"Treatment of chronic hepatitis C in Asia: when east meets west","volume":"24","author":"Yu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"2023091316595833900_jiad016-B28","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1097\/MD.0000000000000690","article-title":"Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"2023091316595833900_jiad016-B29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jfma.2018.10.020","article-title":"Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: the INITIATE study","volume":"118","author":"Liu","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"2023091316595833900_jiad016-B30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.35772\/ghm.2021.01064","article-title":"Taiwan accelerated its efforts to eliminate hepatitis C","volume":"3","author":"Chien","year":"2021","journal-title":"Global Health Med"},{"key":"2023091316595833900_jiad016-B31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4269\/ajtmh.2002.67.145","article-title":"Predicting the prevalence of antibody to hepatitis C virus (HCV) in a community by the prevalence of elevated levels of alanine aminotransferase: a method to identify areas endemic for HCV","volume":"67","author":"Lu","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2023091316595833900_jiad016-B32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.trstmh.2009.03.027","article-title":"Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation","volume":"103","author":"Chiang","year":"2009","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2023091316595833900_jiad016-B33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12072-009-9146-x","article-title":"Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas","volume":"3","author":"Su","year":"2009","journal-title":"Hepatol Int"},{"key":"2023091316595833900_jiad016-B34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int"},{"key":"2023091316595833900_jiad016-B35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jvh.12759","article-title":"Strategies to manage hepatitis C virus infection disease burden-volume 4","volume":"24","author":"Chen","year":"2017","journal-title":"J Viral Hepat"},{"key":"2023091316595833900_jiad016-B36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17571472.2010.11493315","article-title":"An overview of the healthcare system in Taiwan","volume":"3","author":"Wu","year":"2010","journal-title":"London J Prim Care"},{"key":"2023091316595833900_jiad016-B37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3350\/cmh.2020.0150","article-title":"Scaling up the in-hospital hepatitis C virus care cascade in Taiwan","volume":"27","author":"Huang","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"2023091316595833900_jiad016-B38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.kint.2019.10.030","article-title":"Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients","volume":"97","author":"Huang","year":"2020","journal-title":"Kidney Int"},{"key":"2023091316595833900_jiad016-B39","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1136\/gutjnl-2020-323277","article-title":"Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in hemodialysis centers (ERACE-C)","volume":"70","author":"Yu","year":"2021","journal-title":"Gut"},{"key":"2023091316595833900_jiad016-B40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126031","article-title":"Comparison stratagems of post-screening management of anti-HCV positive community residents: simple notification, active referral, or accessible medical care","volume":"10","author":"Kuo","year":"2015","journal-title":"PLoS One"},{"key":"2023091316595833900_jiad016-B41","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.3390\/ijerph19063269","article-title":"Liver disease screening and hepatitis C virus elimination in Taiwan rural indigenous townships: village-by-village screening and linking to outreach hepatology care","volume":"19","author":"Tien","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2023091316595833900_jiad016-B42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14787210.2019.1604221","article-title":"Strategies for the improvement of HCV testing and diagnosis","volume":"17","author":"Chevaliez","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023091316595833900_jiad016-B43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jfma.2019.07.011","article-title":"Hepatitis C virus core antigen is cost effective in community-based screening of active hepatitis C infection in Taiwan","volume":"119","author":"Wang","year":"2020","journal-title":"J Formosan Med Assoc"},{"key":"2023091316595833900_jiad016-B44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"2023091316595833900_jiad016-B45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategies and operational considerations","volume":"38","author":"Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"key":"2023091316595833900_jiad016-B46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40121-021-00424-8","article-title":"Real-world experience with coformulated ledipasvir and sofosbuvir for HIV-positive patients with HCV genotype 2 infection: a multicenter retrospective study","volume":"10","author":"Liou","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023091316595833900_jiad016-B47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.ajkd.2021.03.017","article-title":"Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan","volume":"78","author":"Hu","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2023091316595833900_jiad016-B48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ofid\/ofaa301","article-title":"Micro-elimination of chronic hepatitis C by universal screening plus direct acting antivirals for incarcerated persons in Taiwan","volume":"7","author":"Yang","year":"2020","journal-title":"Open Forum Inf Dis"},{"key":"2023091316595833900_jiad016-B49","author":"Taiwan National Hepatitis C Program Office (TWNHCP), Ministry of Health and Welfare, Taiwan, R.O.C"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_3\/S180\/51544067\/jiad016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_3\/S180\/51544067\/jiad016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:00:49Z","timestamp":1694624449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_3\/S180\/7273019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":49,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2023,9,13]]},"published-print":{"date-parts":[[2023,9,13]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad016","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,9,13]]}}}